Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

A new American Diabetes Association consensus statement provides guidance on screening, diagnosing, and managing metabolic ...

Semaglutide significantly improved liver fibrosis and steatohepatitis resolution in MASH patients over 72 weeks compared to placebo. The study involved 800 patients receiving semaglutide and 400 ...

Semaglutide presents a promising, multi-targeted therapeutic option for addressing the hepatic and systemic consequences of MASH, though final conclusions on long-term clinical outcomes await the ...

Fact checked by Nick Blackmer In a new study, semaglutide reduced liver fat, inflammation, and scarring in people with MASH.Patients also saw improvements in weight, blood sugar, and insulin ...

Altimmune nears a key MASH trial readout, with strong market potential and new liver and alcohol studies supporting growth.

The study participants reflected a diverse population of MASH patients. About 56% had type 2 diabetes, and approximately 73% were classified as obese. This suggests that semaglutide may be ...

All participants also received standard care for MASH. Participants got two liver biopsies to help evaluate the effects of semaglutide. About 56% of participants had type 2 diabetes, and about 73% ...

How does Wegovy (or any form of 2.4 mg dose of semaglutide) help with MASH? That's exactly what this trial set to find out. Researchers conducted a randomized, double-blind, placebo-controlled ...